The statement touches on issues such as the reporting of secondary findings, adult-onset conditions, incest, and non-paternity results.
The deal is still subject to other closing conditions including the approval of BRL's shareholders.
The firms aim to establish the second largest lab services firm in the world to aid drugmakers with clinical trials.
The tests are based on the company's ICE COLD PCR technology, which preferentially enriches mutant DNA sequences in an excess of wild-type DNA.
The Munich-based firm will use the funds to bring its Pharos400 laser-based PCR molecular diagnostic platform to market.
In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.
A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.
A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.
The BabySeq project to study the risks and benefits of sequencing newborns is underway.